7月11日，安序源收到证监会关于赴港上市的备案反馈意见，具体反馈如下： 一、说明AxbioTalentLimited信托设立时间、类型及运作方式、期限、各信托当事人权利义务安排及信 托受益人等情况。 四、关于业务经营，说明：（1）公司及境内运营实体是否涉及开发、运营网站、小程序、APP、公众 号等产品，是否涉及向第三方提供信息内容，提供信息内容的类型以及信息内容安全保护措施；同时说 明收集及储存的用户信息规模、数据收集使用情况，上市前后个人信息保护和数据安全的安排或措施； （2）境内运营实体经营范围、实际业务是否涉及限制或禁止外商投资领域。 近日，安序源向港交所递交上市申请书，拟主板挂牌上市，中金公司和浦银国际担任联席保荐人。据招 股书显示，安序源最近两年来连续亏损。 安序源科技成立于2016年，是一家集成电路生物科技企业，公司的核心产品AxiLona EL-100是中国极少 数能够执行基于电化学、多靶标、快速、低成本和整合式生物分子检测的分子诊断产品。 二、关于搭建离岸架构及返程并购的合规性，说明：（1）搭建离岸架构和返程投资涉及的外汇管理、 境外投资、外商投资、税务管理等监管程序具体履行情况，并就合规性出 ...

Core Viewpoint - Axbio International Limited, a biotechnology company focused on integrated circuit technology, has filed for an IPO on the Hong Kong Stock Exchange, despite reporting consecutive losses over the past two years and not generating revenue from its research products [1][2]. Company Overview - Axbio International Limited was established in 2016 and specializes in molecular diagnostic products, a next-generation electrochemical long-read sequencing platform (EL-NGS), and biochips, along with related services [2]. - The company's product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various testing kits [4]. Financial Performance - The company reported no revenue in 2023, with projected revenue of $47,900 in 2024, primarily from the sale of AxiLona AXP-100 for research purposes [4]. - Financial data for 2023 and 2024 shows: - Revenue: $479,000 in 2024 - Cost of Sales: $175,000 in 2024 - Gross Profit: $304,000 in 2024 - Other Income: $1,935,000 in 2023 and $2,063,000 in 2024 - Total Loss: $22,856,000 in 2023 and $23,466,000 in 2024 [5]. - The losses are primarily attributed to research and administrative expenses, with R&D expenditures of $15.3 million in 2023 and $11.4 million in 2024 [6]. Shareholding and Investment - The company was founded by Dr. Hui Tian and Dr. Igor Ivanov, with Dr. Tian holding 30.44% of the shares, making him the largest single shareholder [7]. - Axbio has received investments from notable institutions including AstraZeneca, CICC, and Yunfeng Capital [9]. Use of IPO Proceeds - The funds raised from the IPO will be allocated for the further development, commercialization, and production of core products AxiLona EL-100 and AxiLona AXP-100, as well as the development of AxiLona AXP-1000 and other pipeline products [9].